BioSpace20h
AstraZeneca Dodges China Questions While Raising 2024 Outlook With Strong Q3 Sales
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
BioSpace5h
Insilico Aces Second Mid-Stage IPF Trial in a Row
In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...
BioSpace5h
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more
BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.
BioSpace20h
Bayer Earnings ‘Not Pretty,’ CEO Bill Anderson Admits As He Urges Calm
Bayer reported a decline of 37% in earnings per share on Tuesday, which sent its stock down 12%. CEO Bill Anderson urged ...
BioSpace8h
Neurogene Shares Tank After Adverse Event Linked to Early-Stage Rett Syndrome Gene Therapy
Analysts did not seem very concerned by the treatment-related serious adverse event, noting that NGN-401 was well-tolerated ...
BioSpace8h
Don’t Call It a Crossover, but Alentis Raises $181M Series D for ADC Work
CEO Roberto Iacone admitted in an interview that the market remains tough, even for a biotech in the red-hot ADC world. But ...
BioSpace7h
23andMe Cuts Headcount by 40%, Drops Drug Discovery Work
In line with the restructuring initiative, 23andMe is looking for strategic opportunities for its pipeline assets, including ...